A case series study investigated the TMB level in 17 patients with advanced HCC who received PD-1 inhibitors and revealed that TMB levels showed no significant variation between patients with stable or responsive disease (ranging from 3–15 mutations/Mb) versus patients with progressive disease (ranging from 4–9 mutations/Mb) [94]. Here, PDCD1 is linked to hepatocellular carcinoma.